Moreover, we introduce an additional level of crosstalk between hypoxia/PHD2-mediated signaling and EGFR-induced tumorigenesis in breast cancer, which is important for the development of novel breast cancer treatment options. This evidence concerns the gene EGFR and breast carcinoma.